Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides).

CONCLUSIONS: Data suggest that, after the issue of the new classification criteria for SpA, biological therapy is being administered earlier than previously in SpA patients and in a higher proportion of patients with nr-axSpA. However, this change in prescribing profile, apparently, has not caused an over-treatment, as patients do not seem to have a lower disease burden than prior to the issue of the criteria. PMID: 29745878 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29745878?dopt=Abstract

Source: Clinical and Experimental Rheumatology - May 12, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research